Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tonabacase - iNtRON Biotechnology

Drug Profile

Tonabacase - iNtRON Biotechnology

Alternative Names: N-Rephasin® SAL200; SAL200

Latest Information Update: 23 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator iNtRON biotechnology
  • Developer iNtRON Biotechnology; Seoul National University Hospital
  • Class Antibacterials; Coliphages; Endolysins; Endopeptidases; Proteins
  • Mechanism of Action Cell wall inhibitors; Peptidoglycan modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Methicillin-resistant Staphylococcus aureus infections
  • No development reported Vancomycin-resistant Staphylococcus aureus infections

Most Recent Events

  • 20 Jun 2019 Pharmacodynamics data from a preclinical study in Methicillin-resistant staphylococcus aureus infections presented at the ASM Microbe 2019 (ASMM-2019)
  • 19 Nov 2018 Tonabacase (SAL200), anti-vancomycin-resistant enterococcal and anti-tuberculosis biologics licensed to Roivant Sciences
  • 07 Jun 2018 Preclinical trials in Methicillin-resistant Staphylococcus aureus infections in South Korea (Intranasal) before June 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top